 Selections from the Alzheimer's Disease Summit: Translating Research Advances Into Clinical Practice
Advances in Neuroimaging and Biomarkers PsychCast™ (71 Minutes)
Faculty: Liana Apostolova, MD, Mark A. Mintun, MD, and Elaine Peskind, MD
This CME Expert Review PsychCast™ is jointly sponsored by the Mount Sinai School of Medicine and MBL Communications.
Release Date: December 2008
Termination Date: December 31, 2010
Estimated time to complete this activity: 1 hour
Medium: The content is delivered by PsychCast™ with a PDF or web-based Posttest
Acknowledgment of Commercial Support: Funding for this activity has been provided by educational grants from Forest Pharmaceuticals Inc., Eisai Inc., Medivation, Inc., and Elan Pharmaceuticals, Inc.
CME Course Director: This activity has been peer-reviewed and approved by James C.-Y. Chou, MD, associate clinical professor of Psychiatry at the Mount Sinai School of Medicine. Review Date: September 24, 2008
Faculty Affiliation
Dr. Apostolova is assistant professor of neurology at UCLA Alzheimer’s Disease Center in Los Angeles, California.
Dr. Mintun is professor of radiology with joint appointments in psychiatry, neurobiology and biomedical engineering; interim director of radiological science; director of the Center for Clinical Imaging Research; and director of the Division of Research Development, at Washington University School of Medicine in St. Louis, Missouri.
Dr. Peskind is Associate Director of the Alzheimer’s Disease Research Center and Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington.
Faculty Disclosure Policy Statement
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
Faculty Disclosure
Dr. Apostolova reports no financial, academic, or other interest in any organization that may pose a conflict of interest.
Dr. Mintun reports no financial, academic, or other interest in any organization that may pose a conflict of interest. He includes discussion of investigational uses of 11C-PIB for evaluation of dementia and risk of Alzheimer’s disease.
Dr. Peskind reports no financial, academic, or other interest in any organization that may pose a conflict of interest.
Dr. Chou reports no affiliation with or relevant financial interest in any organization that may pose a conflict of interest.
Learning Objectives
• Explain the importance of a structural brain scan in the elderly patient with cognitive impairment
• Describe the state of the art understanding of how to use molecular imaging for diagnosis in Alzheimer’s disease
• Recognize the clinical utility of lumbar puncture in the differential diagnosis of dementia and delirium
Target Audience: This activity is designed to meet the educational needs of neurologists, primary care physicians, and psychiatrists.
Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclaimer: These are the opinions of the authors not of the sponsors or supporters. For more information, contact MBL Communications at cme@mblcommunications.com.
Minimum Hardware/Software Requirements
Macintosh: PowerPC processor, Mac OS 8.6, 9.0.4, 9.1, or Mac OS X, 64MB of RAM, 24MB of available hard-disk space, and Safari 1.x or 2.x.
Windows PC: Intel Pentium processor, Microsoft Windows 95 OSR 2.0, Windows 98 and 98 SE, Windows Millennium Edition, Windows NT 4.0 with Service Pack 5, Windows 2000, or Windows XP, 64MB of RAM, 24MB of available hard-disk space, and Internet Explorer 6.x and newer or Firefox 1.x and newer.
This CME Activity and Posttest information file is a PDF (Portable Document Format) document. To view this file, you will need Adobe Acrobat Reader, which is available free at www.adobe.com. Follow the instructions on that page to download and install the software.
Selections from the Alzheimer's Disease Summit: Translating Research Advances Into Clinical Practice
Advances in Neuroimaging and Biomarkers PsychCast™ (71 Minutes)
Faculty: Liana Apostolova, MD, Mark A. Mintun, MD, and Elaine Peskind, MD
Statement of Need and Purpose
Alzheimer’s disease (AD) is a progressive brain disorder that affects cognitive, behavioral, and functional abilities. Patients progress from mild cognitive impairment to death in a span of approximately 10 years, with increasing functional disability, cognitive impairment, and behavioral symptoms. AD currently affects 4.5 million Americans, and its prevalence is rapidly rising. In addition, many patients are not diagnosed until late in their disease progression, and available treatments are underutilized. Research advances must be translated into clinical practice to maximally impact the care of patients. New technologies are evolving to assist clinicians in dementia recognition, including screening exams, computerized neuropsychological test batteries, and neuropsychological testing. Neuroimaging and biomarkers play a growing role in research and clinical practice. Knowing when to apply these new techniques in clinical practice and how to interpret their results is increasingly important to clinicians and patients. AD therapeutics is poised to change dramatically in the next few years. There have been new indications for the use of cholinesterase inhibitors. Improved understanding of the pathophysiology of AD has presented well-informed targets for therapeutic intervention, and disease-modifying agents are currently being tested in clinical trials. Anti-amyloid strategies, neuroprotective strategies, immunotherapies, enzyme inhibitors, and neuroprotective approaches are some of the directions being explored. Practitioners need information about the changing landscape of AD research to respond to patient questions, anticipate new therapeutic directions, and refer to clinical trials.
The Alzheimer’s Disease Summit (ADS), held on May 3, 2008, in Washington, DC, translated cutting-edge research into day-to-day practice. Leading experts discussed the latest research advances in four critical areas—diagnosis, imaging and biomarkers, current treatment, and evolving treatment approaches—and related this new knowledge to clinical practice. This PsychCast, based on information presented at the ADS, presents valuable clinical content to a broad audience of primary care physicians, psychiatrists, geriatricians, and neurologists.
To receive credit for this activity: Listen to the PsychCast™, reflect on the material presented, and complete the online CME Posttest/Evaluation here or to submit the CME Posttest/Evaluation by mail or fax, download a PDF here. To obtain credit, you should score 70% or better. The estimated time to complete the PsychCast™ and the posttest and evaluation is 1 hour. Successful completion of the posttest and evaluation will allow you to claim credit and print a certificate.
Early submission of this posttest is encouraged: please submit by December 1, 2010 to be eligible for credit. If you have any questions, please e-mail cme@mblcommunications.com.
Read the extended CME supplement related to this PsychCast™ activity here
Visit the Alzheimer's Disease Summit website here
Supported by Forest Pharmaceuticals Inc., Eisai Inc., Medivation, Inc., and Elan Pharmaceuticals, Inc. |
Subscribe |
Download |
|
|
|
|
